A citation-based method for searching scientific literature

Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller. Lancet 2004
Times Cited: 2558







List of co-cited articles
717 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
25


2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
23



Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
P M Kearney, L Blackwell, R Collins, A Keech, J Simes, R Peto, J Armitage, C Baigent. Lancet 2008
21


Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
19

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
J Shepherd, S M Cobbe, I Ford, C G Isles, A R Lorimer, P W MacFarlane, J H McKillop, C J Packard. N Engl J Med 1995
18

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
18

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
James Shepherd, Gerard J Blauw, Michael B Murphy, Edward L E M Bollen, Brendan M Buckley, Stuart M Cobbe, Ian Ford, Allan Gaw, Michael Hyland, J Wouter Jukema,[...]. Lancet 2002
16

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
16


Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Salim Yusuf, Jackie Bosch, Gilles Dagenais, Jun Zhu, Denis Xavier, Lisheng Liu, Prem Pais, Patricio López-Jaramillo, Lawrence A Leiter, Antonio Dans,[...]. N Engl J Med 2016
457
15

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
15

Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P Cannon, Eugene Braunwald, Carolyn H McCabe, Daniel J Rader, Jean L Rouleau, Rene Belder, Steven V Joyal, Karen A Hill, Marc A Pfeffer, Allan M Skene. N Engl J Med 2004
15

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, E H Barnes, M Voysey, A Gray, R Collins, C Baigent. Lancet 2012
15

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
14

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F M Sacks, M A Pfeffer, L A Moye, J L Rouleau, J D Rutherford, T G Cole, L Brown, J W Warnica, J M Arnold, C C Wun,[...]. N Engl J Med 1996
14

Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
14

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. Circulation 2019
968
13

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C Baigent, A Keech, P M Kearney, L Blackwell, G Buck, C Pollicino, A Kirby, T Sourjina, R Peto, R Collins,[...]. Lancet 2005
13

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
13

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
John C LaRosa, Scott M Grundy, David D Waters, Charles Shear, Philip Barter, Jean-Charles Fruchart, Antonio M Gotto, Heiner Greten, John J P Kastelein, James Shepherd,[...]. N Engl J Med 2005
13



Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
Naveed Sattar, David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Anton J M de Craen, Sreenivasa Rao Kondapally Seshasai, John J McMurray, Dilys J Freeman, J Wouter Jukema,[...]. Lancet 2010
12

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
12

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.
Haruo Nakamura, Kikuo Arakawa, Hiroshige Itakura, Akira Kitabatake, Yoshio Goto, Takayoshi Toyota, Noriaki Nakaya, Shoji Nishimoto, Masaharu Muranaka, Akira Yamamoto,[...]. Lancet 2006
647
11

High-dose atorvastatin after stroke or transient ischemic attack.
Pierre Amarenco, Julien Bogousslavsky, Alfred Callahan, Larry B Goldstein, Michael Hennerici, Amy E Rudolph, Henrik Sillesen, Lisa Simunovic, Michael Szarek, K M A Welch,[...]. N Engl J Med 2006
11

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou,[...]. Lancet 2005
11

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Christoph Wanner, Vera Krane, Winfried März, Manfred Olschewski, Johannes F E Mann, Günther Ruf, Eberhard Ritz. N Engl J Med 2005
10

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
10


The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Colin Baigent, Martin J Landray, Christina Reith, Jonathan Emberson, David C Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan Craig,[...]. Lancet 2011
9

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
Bengt C Fellström, Alan G Jardine, Roland E Schmieder, Hallvard Holdaas, Kym Bannister, Jaap Beutler, Dong-Wan Chae, Alejandro Chevaile, Stuart M Cobbe, Carola Grönhagen-Riska,[...]. N Engl J Med 2009
9

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
9

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Robert P Giugliano, Christopher P Cannon, Michael A Blazing, José C Nicolau, Ramón Corbalán, Jindřich Špinar, Jeong-Gun Park, Jennifer A White, Erin A Bohula, Eugene Braunwald. Circulation 2018
176
9

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
9

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
9

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Naveed Sattar, Björn Eliasson, Ann-Marie Svensson, Björn Zethelius, Mervete Miftaraj, Darren K McGuire, Annika Rosengren,[...]. N Engl J Med 2018
500
9


Effects of extended-release niacin with laropiprant in high-risk patients.
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins,[...]. N Engl J Med 2014
989
8


Effects of intensive blood-pressure control in type 2 diabetes mellitus.
William C Cushman, Gregory W Evans, Robert P Byington, David C Goff, Richard H Grimm, Jeffrey A Cutler, Denise G Simons-Morton, Jan N Basile, Marshall A Corson, Jeffrey L Probstfield,[...]. N Engl J Med 2010
8

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
8

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen,[...]. Eur Heart J 2016
8

Interpretation of the evidence for the efficacy and safety of statin therapy.
Rory Collins, Christina Reith, Jonathan Emberson, Jane Armitage, Colin Baigent, Lisa Blackwell, Roger Blumenthal, John Danesh, George Davey Smith, David DeMets,[...]. Lancet 2016
918
8

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
G G Schwartz, A G Olsson, M D Ezekowitz, P Ganz, M F Oliver, D Waters, A Zeiher, B R Chaitman, S Leslie, T Stern. JAMA 2001
8

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Terje R Pedersen, Ole Faergeman, John J P Kastelein, Anders G Olsson, Matti J Tikkanen, Ingar Holme, Mogens Lytken Larsen, Fredrik S Bendiksen, Christina Lindahl, Michael Szarek,[...]. JAMA 2005
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.